Conditional drug exemption requires proof that non-scheduled ingredients are therapeutically inert and commercially necessary.

Exemption under a conditional drug notification requires strict compliance with its terms. Where a medicine contains a non-scheduled ingredient, that ingredient must be affirmatively shown to be a pharmaceutical necessity and therapeutically inert, without interfering with the therapeutic or prophylactic activity of the scheduled ingredient. On the record, there was no material evidence or chemical report establishing that dextrose met those conditions, and the controlling Supreme Court precedent was not properly addressed. The exemption was therefore not available, and the product did not qualify for the notification benefit.

---

---

Issues: Whether the presence of dextrose in the product satisfied the conditions of the exemption notification by being a pharmaceutical necessity that was therapeutically inert and did not interfere with the therapeutic or prophylactic activity of the scheduled ingredient.

Analysis: The exemption depended on strict compliance with the notification. Where a medicine contains an ingredient not specified in the schedule, the ingredient must be shown to be a pharmaceutical necessity and must also be therapeutically inert without interfering with the therapeutic or prophylactic activity of the scheduled ingredient. The record did not contain material evidence establishing that the dextrose in the product satisfied these conditions. The appellate authority had not addressed the controlling Supreme Court decision and had not examined the basic evidence or chemical report to determine whether the statutory conditions for exemption were met.

Conclusion: The conditions for exemption were not proved, so the respondent was not entitled to the benefit of the notification.

Ratio Decidendi: Exemption under a conditional drug notification is unavailable unless the non-scheduled ingredient is affirmatively shown to be a pharmaceutical necessity and therapeutically inert without interfering with the activity of the scheduled ingredient.

---